Several reports have suggested that EPO and EPO stimulating agents could promote tumor cell proliferation through its specific receptor (EPOR) and hypoxia in head and neck tumors [39], breast cancer [40] and HCC [41]. Here, EPOR is linked to hepatocellular carcinoma.